1674. Trends in Antimicrobial Susceptibility to Ceftolozane/Tazobactam and Comparators of Pseudomonas aeruginosa from Patients with Respiratory Tract Infections in Five Latin American Countries – SMART 2017-2020

BACKGROUND: Ceftolozane is a cephalosporin specifically developed to have enhanced antibacterial activity against P. aeruginosa. Combined with tazobactam, it was approved by FDA and EMA for hospital-acquired/ventilator-associated bacterial pneumonia. We evaluated trends in the activity of ceftolozan...

Descripción completa

Detalles Bibliográficos
Autores principales: Lob, Sibylle, Hackel, Meredith, Siddiqui, Fakhar, Pavia, Jacqueline, DeRyke, Charles A, Young, Katherine, Motyl, Mary, Sahm, Daniel F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9753037/
http://dx.doi.org/10.1093/ofid/ofac492.1304

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9753037/
http://dx.doi.org/10.1093/ofid/ofac492.1304

Ejemplares similares